VACC
Vaccitech plc [VACC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VACC Stock Summary
In the News
Vaccitech to Present at Upcoming October Investor & Scientific Conferences
OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.
Vaccitech to Present at Upcoming September Investors Conferences
OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.
Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why
Vaccitech PLC Sponsored ADR (VACC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens
Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies. In the VTP-.
Vaccitech to Present at the Jefferies Healthcare Conference
OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virtually.
Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Vaccitech (NASDAQ: VACC) is known to be the spin-off from Oxford University behind AstraZeneca Sars-Cov-2 vaccine.
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.
Wall Street Analysts Believe Vaccitech PLC Sponsored ADR (VACC) Could Rally 113%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Vaccitech PLC Sponsored ADR (VACC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial
Vaccitech plc (NASDAQ: VACC) has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of surface antigen (HBsAg) levels in chronic Hepatitis B patients. Data from an interim analysis of immunogenicity and safety in Groups 1 and 2 were recently reported at the 2021 AASLD The Liver Meeting.
VACC Financial details
VACC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2019-12-31 | 2021-12-31 |
|---|---|---|---|
| Revenue per share | 101.17 | 5.62 | |
| Net income per share | -371.62 | -1.07K | |
| Operating cash flow per share | -231.46 | -683.86 | |
| Free cash flow per share | -237.61 | -707.91 | |
| Cash per share | 239.94 | 4.49K | |
| Book value per share | -471.11 | 5.29K | |
| Tangible book value per share | -463.4 | 4.38K | |
| Share holders equity per share | -471.11 | 5.29K | |
| Interest debt per share | 112.86 | 207.57 | |
| Market cap | 671.81K | 529.35K | |
| Enterprise value | -8.98M | -206.3M | |
| P/E ratio | -0.04 | -0.01 | |
| Price to sales ratio | 0.14 | 1.98 | |
| POCF ratio | -0.06 | -0.02 | |
| PFCF ratio | -0.06 | -0.02 | |
| P/B Ratio | -0.03 | 0 | |
| PTB ratio | -0.03 | 0 | |
| EV to sales | -1.86 | -769.79 | |
| Enterprise value over EBITDA | 0.65 | 4.33 | |
| EV to operating cash flow | 0.81 | 6.33 | |
| EV to free cash flow | 0.79 | 6.12 | |
| Earnings yield | -26.36 | -96.09 | |
| Free cash flow yield | -16.85 | -63.72 | |
| Debt to equity | -1.83 | 0.11 | |
| Debt to assets | 2.16 | 0.1 | |
| Net debt to EBITDA | 0.7 | 4.34 | |
| Current ratio | 2.83 | 20.32 | |
| Interest coverage | -5.57 | -16.95 | |
| Income quality | 0.62 | 0.64 | |
| Dividend Yield | 0 | 0 | |
| Payout ratio | 0 | 0 | |
| Sales general and administrative to revenue | 2.17 | 93.72 | |
| Research and developement to revenue | 2.3 | 61.08 | |
| Intangibles to total assets | 0 | 0.16 | |
| Capex to operating cash flow | 0.03 | 0.04 | |
| Capex to revenue | -0.06 | -4.28 | |
| Capex to depreciation | -1.4 | -1.9 | |
| Stock based compensation to revenue | 0.75 | 61.52 | |
| Graham number | 1.98K | 11.27K | |
| ROIC | 2.61 | 0.3 | |
| Return on tangible assets | -0.93 | -0.21 | |
| Graham Net | -561.63 | 4K | |
| Working capital | 10.5M | 215.61M | |
| Tangible asset value | -22.08M | 208.5M | |
| Net current asset value | -24.87M | 198.61M | |
| Invested capital | -0.08 | 0.03 | |
| Average receivables | 0 | 5.08M | |
| Average payables | 0 | 3.15M | |
| Average inventory | 0 | 0 | |
| Days sales outstanding | 295.91 | 8.51K | |
| Days payables outstanding | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | |
| Receivables turnover | 1.23 | 0.04 | |
| Payables turnover | 0 | 0 | |
| Inventory turnover | 0 | 0 | |
| ROE | 0.79 | -0.2 | |
| Capex per share | -6.14 | -24.05 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0.4 | 0.46 | 0.17 | |
| Net income per share | -0.64 | -0.61 | 0.07 | 0.42 | 0.22 | |
| Operating cash flow per share | -0.59 | -0.36 | -0.18 | -0.23 | 0.32 | |
| Free cash flow per share | -0.6 | -0.38 | -0.21 | -0.15 | 0.25 | |
| Cash per share | 9.78 | 8.6 | 5.39 | 5.17 | 5.37 | |
| Book value per share | 10.02 | 10.13 | 6.8 | 6.84 | 6.55 | |
| Tangible book value per share | 10.04 | 8.37 | 5.64 | 5.71 | 5.44 | |
| Share holders equity per share | 10.02 | 10.13 | 6.8 | 6.84 | 6.55 | |
| Interest debt per share | 0.06 | 0.29 | 0.18 | 0.23 | 0.25 | |
| Market cap | 417.78M | 276.61M | 193.39M | 165.55M | 119.19M | |
| Enterprise value | 175.75M | 69.78M | -467.69K | -18.16M | -72.66M | |
| P/E ratio | -6.56 | -4.58 | 18.62 | 2.64 | 3.62 | |
| Price to sales ratio | 11.94K | -276.61K | 12.88 | 9.7 | 19.33 | |
| POCF ratio | -28.57 | -30.6 | -29.4 | -19.72 | 10.03 | |
| PFCF ratio | -28.18 | -28.98 | -25.21 | -29.66 | 12.58 | |
| P/B Ratio | 1.68 | 1.1 | 0.77 | 0.65 | 0.49 | |
| PTB ratio | 1.68 | 1.1 | 0.77 | 0.65 | 0.49 | |
| EV to sales | 5.02K | -69.78K | -0.03 | -1.06 | -11.79 | |
| Enterprise value over EBITDA | -11.12 | -4.75 | -0.17 | -1.08 | -7.42 | |
| EV to operating cash flow | -12.02 | -7.72 | 0.07 | 2.16 | -6.11 | |
| EV to free cash flow | -11.85 | -7.31 | 0.06 | 3.25 | -7.67 | |
| Earnings yield | -0.04 | -0.05 | 0.01 | 0.09 | 0.07 | |
| Free cash flow yield | -0.04 | -0.03 | -0.04 | -0.03 | 0.08 | |
| Debt to equity | 0.04 | 0.11 | 0.13 | 0.12 | 0.13 | |
| Debt to assets | 0.04 | 0.1 | 0.12 | 0.11 | 0.11 | |
| Net debt to EBITDA | 15.31 | 14.07 | -69.91 | -10.97 | -19.59 | |
| Current ratio | 30.05 | 20.32 | 14 | 18.6 | 15.58 | |
| Interest coverage | 0 | -926 | 8.84 | 208.91 | 7.3 | |
| Income quality | 0.92 | 0.6 | -2.53 | -0.53 | 1.45 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 353.46 | -9.79K | 0.24 | 0.38 | -1.81 | |
| Research and developement to revenue | 103.83 | -5.67K | 0.64 | 0.57 | 1.7 | |
| Intangibles to total assets | 0 | 0.16 | 0.15 | 0.15 | 0.15 | |
| Capex to operating cash flow | 0.01 | 0.06 | 0.17 | -0.33 | -0.2 | |
| Capex to revenue | -5.77 | 506 | -0.07 | 0.16 | -0.39 | |
| Capex to depreciation | -1.94 | -1.41 | -1.13 | 2.83 | -2.03 | |
| Stock based compensation to revenue | 249.6 | -6.54K | 0.27 | 0.16 | 0.18 | |
| Graham number | 12.01 | 11.76 | 3.27 | 8.06 | 5.71 | |
| ROIC | 0.07 | 0.11 | -0.01 | -0.13 | -0.06 | |
| Return on tangible assets | -0.06 | -0.06 | 0.01 | 0.06 | 0.04 | |
| Graham Net | 9.55 | 7.65 | 4.97 | 4.7 | 4.74 | |
| Working capital | 248.19M | 215.61M | 214.3M | 214.13M | 204.59M | |
| Tangible asset value | 249.91M | 208.5M | 209.87M | 212.29M | 202.46M | |
| Net current asset value | 246.8M | 198.61M | 197.8M | 196M | 187.29M | |
| Invested capital | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Average receivables | 4.8M | 0 | 14.57M | 19.97M | 13.77M | |
| Average payables | 4.76M | 0 | 3.54M | 4.57M | 3.44M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 14.39K | -562.41K | 137.24 | 89.92 | 153.07 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.01 | 0 | 0.66 | 1 | 0.59 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.06 | -0.06 | 0.01 | 0.06 | 0.03 | |
| Capex per share | -0.01 | -0.02 | -0.03 | 0.08 | -0.06 |
VACC Frequently Asked Questions
What is Vaccitech plc stock symbol ?
Vaccitech plc is a GB stock and trading under the symbol VACC
What is Vaccitech plc stock quote today ?
Vaccitech plc stock price is $2.1601 today.
Is Vaccitech plc stock public?
Yes, Vaccitech plc is a publicly traded company.
Company Profile
- Volume Average 52.08K
- Market Capitalization 111.52M
- Employee 72
- CEO Mr. William J. Enright MBA
- Headquarters Oxford,GB
- IPO Date 2021-04-30
-
Website
https://www.vaccitech.co.uk 
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
